DK3307299T3 - Kombinationssammensætninger til behandling af lidelser krævende fjernelse eller ødelæggelse af uønskede celleformeringer - Google Patents
Kombinationssammensætninger til behandling af lidelser krævende fjernelse eller ødelæggelse af uønskede celleformeringer Download PDFInfo
- Publication number
- DK3307299T3 DK3307299T3 DK16730498.9T DK16730498T DK3307299T3 DK 3307299 T3 DK3307299 T3 DK 3307299T3 DK 16730498 T DK16730498 T DK 16730498T DK 3307299 T3 DK3307299 T3 DK 3307299T3
- Authority
- DK
- Denmark
- Prior art keywords
- destruction
- treatment
- unwanted cell
- combination compositions
- required removal
- Prior art date
Links
- 230000006378 damage Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/738,551 US20160361380A1 (en) | 2015-06-12 | 2015-06-12 | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
| PCT/IB2016/053483 WO2016199112A1 (en) | 2015-06-12 | 2016-06-13 | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3307299T3 true DK3307299T3 (da) | 2021-03-22 |
Family
ID=56137476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16730498.9T DK3307299T3 (da) | 2015-06-12 | 2016-06-13 | Kombinationssammensætninger til behandling af lidelser krævende fjernelse eller ødelæggelse af uønskede celleformeringer |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20160361380A1 (da) |
| EP (1) | EP3307299B1 (da) |
| JP (1) | JP6941605B2 (da) |
| KR (1) | KR102720001B1 (da) |
| CN (1) | CN108135974A (da) |
| AU (1) | AU2016275368B2 (da) |
| DK (1) | DK3307299T3 (da) |
| EA (1) | EA038314B1 (da) |
| ES (1) | ES2876358T3 (da) |
| HR (1) | HRP20210462T1 (da) |
| HU (1) | HUE053665T2 (da) |
| IL (1) | IL256230B (da) |
| LT (1) | LT3307299T (da) |
| MX (1) | MX383809B (da) |
| PL (1) | PL3307299T3 (da) |
| PT (1) | PT3307299T (da) |
| RS (1) | RS61685B1 (da) |
| SI (1) | SI3307299T1 (da) |
| WO (1) | WO2016199112A1 (da) |
| ZA (1) | ZA201800083B (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
| US10172910B2 (en) * | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
| US10532081B2 (en) | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
| US10335453B2 (en) | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
| WO2019055648A1 (en) * | 2017-09-14 | 2019-03-21 | Tufts Medical Center, Inc. | METHOD OF TREATMENT AND DIAGNOSIS OF PROSTATE CANCER |
| US10835538B2 (en) | 2018-03-28 | 2020-11-17 | Nymox Corporation | Method of treating benign prostatic hyperlasia with antibiotics |
| US20200061150A1 (en) | 2018-08-23 | 2020-02-27 | Nymox Corporation | Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function |
| SG11202103662VA (en) * | 2018-12-05 | 2021-06-29 | Urovant Sciences Gmbh | Vibegron for the treatment of overactive bladder symptoms |
| US11278588B2 (en) | 2019-05-13 | 2022-03-22 | Nymox Corporation | Method of treating lower urinary tract symptoms with fexapotide triflutate |
| US20200360466A1 (en) | 2019-05-13 | 2020-11-19 | Nymox Corporation | Method of improving lower urinary tract symptoms |
| US11298400B2 (en) * | 2019-05-13 | 2022-04-12 | Nymox Corporation | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS |
| US11231421B2 (en) | 2019-07-31 | 2022-01-25 | Nymox Corporation | Methods of treating multifocal cancer |
| US11331374B2 (en) | 2019-07-31 | 2022-05-17 | Nymox Corporation | Focal treatment of prostate cancer |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3423507A (en) | 1966-02-25 | 1969-01-21 | Schering Corp | Method of treating benign prostratic hypertrophy |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4329364A (en) | 1974-09-11 | 1982-05-11 | Schering Corporation | Antiandrogenic agents and methods for the treatment of androgen dependent disease states |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE2817157A1 (de) | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
| FR2465486A1 (fr) | 1979-09-21 | 1981-03-27 | Roussel Uclaf | Nouvelle application utilisant la lh-rh ou des agonistes |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3121153A1 (de) | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie" |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4775660A (en) | 1984-08-02 | 1988-10-04 | Fernand Labrie | Treatment of breast cancer by combination therapy |
| US4659695A (en) | 1985-02-08 | 1987-04-21 | Fernand Labrie | Method of treatment of prostate cancer |
| US4760053A (en) | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
| FR2582513B1 (fr) | 1985-05-28 | 1988-08-05 | Synthelabo | Compositions pharmaceutiques contenant de l'alfuzosine |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US5212176A (en) | 1990-06-29 | 1993-05-18 | Abbott Laboratories | R(+)-terazosin |
| NZ241979A (en) | 1991-03-20 | 1996-01-26 | Merck & Co Inc | Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker |
| WO1994008040A1 (en) | 1992-09-25 | 1994-04-14 | Synaptic Pharmaceutical Corporation | Dna encoding human alpha 1 adrenergic receptors and uses thereof |
| US5403847A (en) | 1992-11-13 | 1995-04-04 | Synaptic Pharmaceutical Corporation | Use of α1C specific compounds to treat benign prostatic hyperlasia |
| EE9700209A (et) | 1994-11-16 | 1998-04-15 | Synaptic Pharmaceutical Corporation | Dihüdropürimidiinid ja nende kasutamine |
| ATE454445T1 (de) | 1998-11-10 | 2010-01-15 | Univ North Carolina | Virusvektoren und verfahren für ihre herstellung und verabreichung. |
| BR0207638A (pt) | 2001-03-08 | 2004-07-27 | Nymox Pharmaceuticals Corp | Métodos de uso de proteìna de filamento neural para tratar tumores e outras condições que requerem a remoção ou destruição de células |
| KR20040029968A (ko) * | 2001-05-04 | 2004-04-08 | 니목스 코포레이션 | 신경 사 단백질에 대한 항체를 사용하여 세포 사멸을억제하는 방법 |
| ATE300951T1 (de) * | 2001-05-16 | 2005-08-15 | Nymox Corp | Prävention des zelltodes durch verwendung der segmente der neurofilamentproteine |
| JP4584573B2 (ja) | 2001-05-25 | 2010-11-24 | ナイモックス コーポレーション | 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド |
| MXPA04000561A (es) * | 2001-07-19 | 2005-02-17 | Nymox Corp | Peptidos eficaces en el tratamiento de tumores y otras condiciones que requieren la remocion o destruccion de celulas. |
| CN100432103C (zh) * | 2001-07-19 | 2008-11-12 | 尼莫克斯股份有限公司 | 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽 |
| EP1714979A3 (en) * | 2001-11-16 | 2007-04-25 | Nymox Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| US7317077B2 (en) | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| EP1961418B1 (en) * | 2005-11-15 | 2012-04-04 | Cheng, Jingcai | The use of isothiocyanates compounds in treating prostatic diseases and skin cancer |
| SI1994152T1 (sl) * | 2006-02-28 | 2013-05-31 | Nymox Corporation | Peptidi uäśinkoviti pri zdravljenju tumorjev in ostalih stanj, ki zahtevajo odstranitev ali uniäśenje celic |
| CN101400364A (zh) * | 2006-03-10 | 2009-04-01 | 尼莫克斯股份有限公司 | 用基于神经丝状蛋白的肽预防或降低癌症风险或发病率的方法 |
| JP2014510045A (ja) * | 2011-02-08 | 2014-04-24 | ハロザイム インコーポレイテッド | ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用 |
| JP2016514671A (ja) * | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
-
2015
- 2015-06-12 US US14/738,551 patent/US20160361380A1/en active Pending
-
2016
- 2016-06-13 PT PT167304989T patent/PT3307299T/pt unknown
- 2016-06-13 CN CN201680047169.XA patent/CN108135974A/zh active Pending
- 2016-06-13 PL PL16730498T patent/PL3307299T3/pl unknown
- 2016-06-13 KR KR1020187000969A patent/KR102720001B1/ko active Active
- 2016-06-13 RS RS20210324A patent/RS61685B1/sr unknown
- 2016-06-13 EP EP16730498.9A patent/EP3307299B1/en active Active
- 2016-06-13 EA EA201890045A patent/EA038314B1/ru unknown
- 2016-06-13 DK DK16730498.9T patent/DK3307299T3/da active
- 2016-06-13 LT LTEP16730498.9T patent/LT3307299T/lt unknown
- 2016-06-13 WO PCT/IB2016/053483 patent/WO2016199112A1/en not_active Ceased
- 2016-06-13 HU HUE16730498A patent/HUE053665T2/hu unknown
- 2016-06-13 HR HRP20210462TT patent/HRP20210462T1/hr unknown
- 2016-06-13 SI SI201631130T patent/SI3307299T1/sl unknown
- 2016-06-13 MX MX2017016106A patent/MX383809B/es unknown
- 2016-06-13 JP JP2018516657A patent/JP6941605B2/ja not_active Expired - Fee Related
- 2016-06-13 AU AU2016275368A patent/AU2016275368B2/en not_active Ceased
- 2016-06-13 ES ES16730498T patent/ES2876358T3/es active Active
-
2017
- 2017-12-10 IL IL256230A patent/IL256230B/en active IP Right Grant
-
2018
- 2018-01-05 ZA ZA2018/00083A patent/ZA201800083B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017016106A (es) | 2018-08-01 |
| CA2992174A1 (en) | 2016-12-15 |
| CN108135974A (zh) | 2018-06-08 |
| SI3307299T1 (sl) | 2021-04-30 |
| JP2018517772A (ja) | 2018-07-05 |
| HK1254080A1 (en) | 2019-07-12 |
| HRP20210462T1 (hr) | 2021-05-14 |
| PL3307299T3 (pl) | 2021-07-05 |
| KR20180035788A (ko) | 2018-04-06 |
| ZA201800083B (en) | 2019-07-31 |
| IL256230B (en) | 2021-04-29 |
| HUE053665T2 (hu) | 2021-07-28 |
| US20160361380A1 (en) | 2016-12-15 |
| IL256230A (en) | 2018-02-28 |
| AU2016275368A1 (en) | 2018-02-01 |
| PT3307299T (pt) | 2021-03-26 |
| ES2876358T3 (es) | 2021-11-12 |
| KR102720001B1 (ko) | 2024-10-18 |
| MX383809B (es) | 2025-03-14 |
| EP3307299A1 (en) | 2018-04-18 |
| LT3307299T (lt) | 2021-04-12 |
| AU2016275368B2 (en) | 2022-03-03 |
| NZ738853A (en) | 2024-05-31 |
| WO2016199112A1 (en) | 2016-12-15 |
| EP3307299B1 (en) | 2020-12-23 |
| RS61685B1 (sr) | 2021-05-31 |
| EA038314B1 (ru) | 2021-08-09 |
| JP6941605B2 (ja) | 2021-09-29 |
| EA201890045A1 (ru) | 2018-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3307299T3 (da) | Kombinationssammensætninger til behandling af lidelser krævende fjernelse eller ødelæggelse af uønskede celleformeringer | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3349758T3 (da) | Fremgangsmåder til behandling af arenaviridae-virusinfektioner | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3612215T3 (da) | Sammensætninger til behandling af lungeinflammation | |
| DK3600270T3 (da) | Forbindelser og sammensætninger til behandling af hæmatologiske lidelser | |
| DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3285803T3 (da) | Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine | |
| DK3102213T3 (da) | Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3503890T3 (da) | Anvendelse af pridopidin til behandling af dystonier | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
| DK3081263T3 (da) | Sammensætninger og redskaber til behandling af glaukom | |
| DK3307296T3 (da) | Timp2 til anvendelse til behandling af aldringsassocierede tilstande | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3203997T3 (da) | Valproinsyre til behandling eller forebyggelse af patologiske tilstande forbundet med overskydende fibrinaflejring og/eller trombedannelse | |
| DK3134084T3 (da) | Fremgangsmåde til behandling af lungeadenokarcinom | |
| DK3324824T3 (da) | Fremgangsmåde til behandling af binokulare dysfunktioner | |
| DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
| DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi |